Modified peptide

Abstract

The invention provides a peptide based on biologically active CCK-8 having improved characteristics for the treatment of obesity and/or type 2 diabetes wherein the primary structure of CCK-8 is: Asp 1 Tyr 2 (SO 3 H)-Met 3 Gly 4 Trp 5 Met 6 Asp 7 Phe 8 amide (SEQ ID NO:1) and wherein the peptide has at least one amino add substitution and/or modification and is not Asp 1 -glucitol CCK-8. The invention also provides the use of the peptide in the preparation of a medicament to inhibit food intake, induce satiety, stimulate insulin secretion, moderate blood glucose excursions, enhance glucose disposal and/or exhibit enhanced stability in plasma compared to native CCK-8 and/or for treatment of obesity and/or type 2 diabetes.

1. An isolated peptide based on biologically active cholecystokinin-8 (CCK-8) (SEQ ID NO: 1), wherein said peptide is SEQ ID NO: 1, wherein pGlu-Gln is attached to the N-terminal Asp. 
     
     
       2. A pharmaceutical composition comprising the peptide of  claim 1  in admixture with a pharmaceutically acceptable excipient. 
     
     
       3. The pharmaceutical composition of  claim 2 , wherein the pharmaceutically acceptable excipient is suitable for delivery through transdermal, nasal inhalation, oral or injected routes. 
     
     
       4. The pharmaceutical composition of  claim 2 , further comprising native or derived analogues of leptin, exendin, islet amyloid polypeptide or bombesin.